About Us
Juno Pharmaceuticals is a rapidly-growing global specialty pharmaceutical company that was founded in 2011 by group of experienced international pharmaceutical executives.
To date we have launched a wide range of differentiated generic and branded pharmaceutical products in our territories, with approvals pending for an extended list of additional products.
Our product portfolio and pipeline covers a broad spectrum of therapeutic areas and formats, including oral solid dosages, injectable medications, suspensions, ophthalmic solutions, creams and patches.
History
Juno at a Glance
Where Are We Based?
What Do We Offer?
What Are We Looking For?
If you would like to discuss a business opportunity with Juno, please contact Jesse Buckstein, Director of Corporate Development today.
Our Businesses
Please roll over the logos or map points for further information
A fully-integrated British pharmaceutical company offering complete product management solutions to its partners. Aspire specializes in the licensing, registration and commercialization of both branded and generic medicines, with a clear focus on value and sustainability.
Aspire has a proven track record of delivering service to its customers and value to its partners. It invests in product developments that are differentiated and designed to better meet the needs of UK healthcare professionals and patients alike.
Go to Website
Juno’s Australian subsidiary focuses on registering and promoting innovative product presentations and securing treatments for high-priority unmet medical needs. Juno aims to be a leading partner to hospitals across Australia in the provision of specialty hospital medicines and medication delivery systems.
The Juno Australia team has substantial expertise in ensuring reliable commercial activity for maturing brands and/or close-to-patent-expiry brands, which benefits our partners by allowing them to refocus important resources to new product launch opportunities. We are constantly seeking innovative products to in-licence or acquire for the Australian market, and we excel in the development of novel registration pathways for complex generic products.
Go to Website
Contura is a UK-based pan-European specialty pharmaceutical company that primarily focuses on products catering to the European urology and urogynaecology markets.
Contura seeks to acquire, license and distribute pharmaceutical products and medical devices aimed at its target markets. Its products are sold throughout Europe by Contura’s dedicated sales force and where Contura retains IP rights to products outside of Europe, it establishes distribution relationships with expert industry partners for ex-EU territories.
Go to Website
MDA is a Canadian pharmaceutical company principally engaged in commercializing top quality, hospital based, generic and value-added products. MDA is developing a sustainable & differentiated pharmaceutical business that delivers value to customers, business partners, & the Canadian healthcare system alike.
MDA’s strategic focus is on the in-licensing and commercialisation of specialty generics and hospital injectable medications, particularly those that face limited competition & inherent barriers to market entry. MDA also works with a select group of partners to develop limited and/or difficult to manufacture generics and novel drug delivery mechanisms that satisfy untapped market demand.
Go to Website
Kahma is a diversified South African healthcare company that distributes a comprehensive line of vaccines, niche retail & hospital generic medications, hospital-based medical devices, surgical equipment, and much more.
Kahma’s principal shareholders and senior managers were instrumental in building the first black economically empowered (BEE) healthcare company in South Africa (Litha Healthcare), which was listed on the South African Stock Exchange (JSE) before eventually being acquired by Endo in 2015. Their domestic regulatory expertise coupled with their premier network of hospital & retail contacts make Kahma a rising leader in the South African healthcare space.
Go to Website
Juno OTC focuses on sourcing, registering and distributing private label and branded over-the-counter (OTC) medications in Canada. Juno OTC’s management team has longstanding and extensive relationships with all of the leading Canadian pharmaceutical retailers and considerable expertise in ensuring best in class commercial supply chain and customer management.
We work with both our suppliers and customers alike to identify optimal new product opportunities within our market and we specialize in managing all aspects of our products’ commercialization processes, from licensing and registration through to ordering and distribution.
South African-based Trinity Pharma, part of the TriVest Group, is a registered pharmaceutical company committed to promoting affordable and high quality pharmaceutical products and services in Sub-Saharan Africa. This is done by partnering with leading international and local pharmaceutical companies.
By partnering with leading European, North American and Asian principals, Trinity Pharma offers access to African markets through their regulatory consultancy services and/or product commercialisation capabilities. Trinity Pharma supplies generics to the largest pharmaceutical retailers in South Africa, and ultimately Africa. Effectively, they service the entire range of healthcare products through their extensive industry experience, knowledge, networks and partnerships.
Go to Website
Our Capabilities
Global acquisition and in-licensing of specialty generic and branded pharmaceuticals and biologics, including mature brands and first-to-market generics. We utilize our access to medical specialists to identify key therapeutic needs/opportunities across our territories and leverage a global network of industry contacts to source ideal product development and supply partners.
Veteran regulatory affairs professionals with decades of industry experience. We have excellent relationships with the likes of the European Medicines Agency (EMA), the American Food and Drug Administration (FDA), Canada’s Therapeutic Products Directorate (TPD), Australia’s Therapeutic Goods Administration (TGA), and South Africa’s Medicines Control Council (MCC) and our team specializes in developing creative product submission strategies that reliably facilitate rapid market access for in-licensed products.
Numerous employees throughout our territories dedicated to reliably coordinating the movement of our products from point of origin to consumption.
Expert management of hospital tenders and retail relationships coupled with the development and successfully execution of novel product commercialization and reimbursement strategies.
In house IP experts who specialize in the evaluation of brand patent landscapes and the development of novel non-infringement and/or patent invalidation strategies.
“Juno will become a prominent international pharmaceutical company that supplies value-added and differentiated specialty products to global markets. Juno will build bridges to unmet medical needs through disciplined investment and successful application of creative business principles, ensuring that its customers and patient groups have access to the medicines they need at all times.”
Our Team
.
Ian Jacobson
Chief Executive Officer
Ian Jacobson has over 30 years of pharmaceutical industry experience.
Prior to founding Juno Pharmaceuticals, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010 and he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and he played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD.
Prior to his work at Arrow, Ian was involved with Par Pharmaceuticals (US) in the Office of the President, Genpharm Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive.
Ian Jacobson
Chief Executive Officer
Mark Roberts
Chief Executive Officer
Mark Roberts has worked in global pharmaceutical markets for over 20 years.
Before joining Juno, Mark worked at Zydus Cadila as VP Global Licensing (2009 – 2011) where he was responsible for establishing a global licensing business unit focused on generics, bio-generics and branded products.
Prior to his work at Zydus, Mark oversaw the set up and management of a new global licensing business unit at Pliva (division of Barr Labs, eventually acquired by Teva), where he had full responsibility for the establishment and expansion of Pliva’s licensing activities and strategic alliances in Europe, South Africa, Asia Pacific and North America. He also formerly worked for the Helm group from 1997-2003, where he ran pharmaceutical licensing and distribution for South Africa and the USA.
Mark Roberts
Chief Operating Officer
Craig Podolsky
Chief Financial Officer
Craig Podolsky has over 10 years of pharmaceutical industry experience.
Prior to co-founding Juno in 2011, Craig worked for Cobalt Pharmaceuticals in its business development group. He was responsible for negotiating product license and supply agreements for Cobalt’s OTC and generic divisions, and was Cobalt’s primary lead on all global M&A transactions.
Craig Podolsky
Chief Financial Officer
.
.
Jon May
Business Development Director
Jon May has over 20 years of global pharmaceutical product development experience.
Prior to joining Juno in 2016, Jon served as VP Strategic Development and was a key senior management team member at Pharmathen (2008-2016), where he principally oversaw and managed the company’s product portfolio, API functions, direct spend and strategic alliances.
Prior to his work at Pharmathen, Jon worked for Mylan (Merck Generics) from 1995-2008 in various technical functions, and prior to that he worked for SmithKline Beecham Animal Health in various product development and regulatory functions.
Jon May
Business Development Director
Andrew Brown
Head of Intellectual Property
Andrew Brown is a Chartered UK and European Patent Attorney with over 20 years’ of pharmaceutical industry experience. Before joining Juno in 2016, Andrew served as the Head of IP at Pharmathen, and prior to that he served in a myriad of high profile IP roles at various leading pharmaceutical companies, including Senior Patent Attorney at AstraZeneca and IP Director at Teva.
Andrew Brown
Head of Intellectual Property
Jesse Buckstein
Director of Corporate Development
Jesse joined Juno in 2014, where his responsibilities include spearheading due diligence and deal structuring on global M&A opportunities, negotiating and setting up joint ventures, designing and implementing tools to streamline Juno’s internal processes, and drafting and reviewing license and supply contracts with Juno’s contract manufacturing/product development partners.
Prior to joining Juno, Jesse worked in the commercial finance department of TD Bank, where he managed & actively added to a portfolio of over 100 diverse businesses, underwriting a wide range of acquisition, real estate, equipment, and working capital related loans on behalf of his clients. He previously worked for Tandem Expansion Fund, a growth capital investor in Canadian tech companies, where he assisted in acquisition-related due diligence and built a number of databases to help streamline the fund’s operations.
Jesse Buckstein
Director of Corporate Development
.
.
Richard Jacques Ph.D.
Licensing & Business Development Manager
Richard Jacques has over 10 years of pharmaceutical experience gained across a range of academic, industrial and business environments.
Prior to joining Juno in 2015, Richard obtained a Ph.D in small molecule-focused molecular pharmacology from the University of East Anglia’s School of Pharmacy, before subsequently moving into a postdoctoral teaching position at this institution. During this time, Richard forged academic research collaborations with numerous international pharmaceutical companies. Richard also formerly worked in industrial R&D for GlaxoSmithKline at GSK’s Medicines Research Centre.
Richard Jacques Ph.D.
Business Development Manager
CVS Murthy
General Manager India
CVS Murthy has over 20 years of pharmaceutical industry experience. He is responsible for managing Juno’s product sourcing and distribution from Indian suppliers and generally supporting Juno’s business development activities with its global partners.
Prior to joining Juno, Murthy served as General Manager – Indian Operations for Arrow Pharmaceuticals and prior to that he served in a range of business development roles for several leading Indian pharmaceutical companies, including Dr. Reddy’s and Alembic.
CVS Murthy
General Manager India
.
.
News
MELBOURNE, AUSTRALIA – Juno Pharmaceuticals Pty Ltd is pleased to announce the acquisition of a local portfolio of essential injectable medicines from AstraZeneca Pty Ltd. This acquisition will see Juno’s product range grow to over 60 molecules, focussed mainly in the hospital segment.
As part of the acquisition, Juno will receive the intellectual property and regulatory approvals for ten products (eight unique molecules), along with associated contracts and agreements.
This acquisition is the second Juno has made since commencing sales in 2015 and is another milestone in Juno’s continued growth and vision to be the leader in supply of off-patent products in hospitals across Australia and New Zealand.
These critical medicines play a vital role in patient care in Australian and New Zealand hospitals. Our focus at Juno is to build a compelling portfolio that meets the local and unique needs of Australian and New Zealand hospitals, noted Juno CEO & Managing Director, Mark Crotty.
The agreement comes into effect on April 1st, 2019 and Juno’s key account managers will work closely with customers and wholesalers to ensure a smooth transition.
From April 1st, 2019, all commercial enquiries regarding the products below should be directed to your local Juno representative. Any adverse event reporting, product complaints and medical enquiries should directed to Juno Medical Information on 1800 620 076 or medical-enquiries@junopharm.com.au
- ASTRAZENECA SODIUM CHLORIDE 20% 2g/10mL injection BP ampoule
- ASTRAZENECA POTASSIUM CHLORIDE 750mg/10mL injection ampoule
- ASTRAZENECA ATROPINE SULFATE 600 microgram/1mL injection BP ampoule
- ASTRAZENECA ATROPINE SULFATE 1.2mg/1mL injection BP ampoule
- ASTRAZENECA SUXAMETHONIUM CHLORIDE 100mg/2mL injection BP ampoule
- ASTRAZENECA NEOSTIGMINE METHYLSULFATE 0.5mg/1mL injection BP ampoule
- ASTRAZENECA NEOSTIGMINE METHYLSULFATE 2.5mg/1mL injection BP ampoule
- ASTRAZENECA PANCURONIUM BROMIDE 4mg/2mL injection BP ampoule
- ASTRAZENECA PETHIDINE HYDROCHLORIDE 100mg/2mL injection BP ampoule
- ASTRAZENECA FENTANYL 100 microgram/2mL (as citrate) injection ampoule
- ASTRAZENECA FENTANYL 500 microgram/10mL (as citrate) injection ampoule
About Juno
Juno Pharmaceuticals is a rapidly growing, local Australian and New Zealand business and are experts in off-patent prescription pharmaceuticals. Juno’s portfolio includes medicines across a diverse range of therapeutic areas, with hospital products the core focus of the business. The acquisition of this portfolio is in line with Juno’s mission to improve the health of society, through delivering high quality products to patients, and value to hospitals, the government and tax payers.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and www.astrazeneca.com.au.
WEST PALM BEACH, FL / ACCESSWIRE / November 21, 2018 / MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has agreed a licensing deal with Aspire Pharma Ltd. (Aspire) in the UK for the Mitomic® Prostate Test (MPT™). On the heels of recent news that MDNA's CE marked MPT™ Real-Time PCR kit is now commercially available, this is the first international partner to be announced by MDNA and is the start of the global roll-out of MPT™through a growing network of distribution partners.
The test needs only a simple blood sample to be taken which is then processed in a clinical laboratory using MDNA's proprietary CE-IVD kit. MPT™ is the world's first blood test to use a unique biomarker that is independent of PSA and age and to be made available in a simple real-time PCR format. The test delivers unparalleled performance for the detection of clinically significant prostate cancer.
Currently, prostate cancer screening is heavily reliant on the measurement of PSA levels, which can give notoriously high false-positive results. This leads to millions of men being wrongly referred for prostate biopsy. With a 92% sensitivity, MPT™ can accurately determine whether clinically significant prostate cancer is present, so men can be referred for immediate medical intervention. MPT™ also has a higher than 99% negative predictive value which means that men with a negative MPT result can safely delay or avoid an invasive prostate biopsy as there is a very low probability that significant cancer would be found.
"We are proud to announce our new partnership with Aspire, and excited to be working with their seasoned team. Aspire's complementary product portfolio, extensive regulatory experience, and strong relationships with key hospitals and urologists in the UK make them an ideal strategic partner for us." said Chris Mitton, CEO of MDNA Life Sciences. "The forthcoming launch of MPT™ with Aspire will expand access to our novel technology and bring significant advances to the way clinicians in the UK approach prostate cancer screening."
Graham Fraser-Pye, Managing Director of Aspire added, "We take great pride in the fact that we are working alongside MDNA Life Sciences to bring this exciting new test to the UK market. Diagnosis of prostate cancer has, until now, been lagging behind other cancers and we believe that with the launch and subsequent further use of this test, that will no longer be the case."
About Aspire Pharma Ltd.
Founded in 2009, Aspire Pharma Ltd is a British pharmaceutical company supplying a mix of innovative branded and generic pharmaceuticals, medical devices, OTC products and diagnostics, across multiple therapeutic classes. Recently listed as one of the top ten fastest growing companies in the sector, Aspire Pharma products continue to provide significant clinical solutions for UK patients, while delivering meaningful economic benefits for the National Health Service. For further information on Aspire Pharma, its vision, people and products, visit www.aspirepharma.co.uk.
info@aspirepharma.co.uk
+44 (0)1730 231148
www.aspirepharma.co.uk
About MDNA Life Sciences Inc.
MDNA Life Sciences, Inc. - www.mdnalifesciences.com - is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA. This innovative platform is a highly effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. It has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases.
The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. Following the successful development of the prostate test, work on tests for endometriosis and ovarian cancer is at an advanced stage and biomarkers have been identified for other cancers such as lung, breast, uterine, cervical, bladder, colorectal, and melanoma.
For further information, please contact:
Christopher Mitton
+1 844-321-6362
c.mitton@mdnalifesciences.com
www.mdnalifesciences.com
SOURCE: MDNA Life Sciences Inc.
MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce that Amgen Australia have appointed us as their distribution partner for the exclusive marketing and distribution of291 Amgen’s biologic medicines Neulasta (Pegfilgrastim) and the launch of Ristempa (Pegfilgrastim). This will be effective 1 March 2018.
Under the terms of this agreement, Juno will be responsible for the commercial management of these brands in Australia. Amgen will continue to be the sponsor of these brands on the Australian Register of Therapeutic Goods (ARTG) and there will be no changes to the product, packaging, labelling and wholesale distribution of Neulasta. We will ensure there is no interruption to the service provided, and your local Juno Key Account Manager will work with you to provide a smooth transition.
Juno Pharmaceuticals is a rapidly growing, local Australian and New Zealand business with expertise in both biosimilars and off patent medicines. Members of the Juno team have had previous experience in the launch and management of a number of biosimilars both in Australia and abroad, including the first and leading biosimilar filgrastim in Australia. Juno’s current portfolio includes medicines across a diverse range of therapeutic areas, with hospital products the core focus of the business and a strong pipeline of complex molecules.
This partnership is a major milestone in Juno’s continued growth and strategy of diversification and expansion into the biologic and biosimilar markets. The partnership is also in line with Juno’s mission to improve the health of society, through delivering high quality products to patients, and value to hospitals, the government and tax payers.
Speciality European Pharma Limited (“SEP”), the parent of a European healthcare group, is pleased to announce the rebranding of itself and each of its subsidiaries as Contura (“the Group”). The rebrand will consolidate the Group under a single corporate identity and positions it for future growth.
“I am pleased to see Contura moving into the next stage of its development, consolidating its position as a leading manufacturer and distributor of speciality medical device and pharmaceutical products. Contura has grown rapidly over recent years and I look forward to our journey as we continue to build on our existing products whilst expanding into new therapy areas with our hydrogel platform. With the recent filing of our premarket approval application for Bulkamid in the United States we also anticipate significant geographic expansion for our products in the years ahead.”
Patrick Banks, Chief Executive Officer.
About SEP and Contura
The Group specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily in the fields of urology and urogynaecology. Its lead products are:
Bulkamid®
Aquamid®
Mitem®
Regurin® XL
Cystistat®
The Group was founded in 2000 and has built an experienced and accomplished management team. It came together as a result of SEP’s acquisition of Contura A/S, a Danish company based in Copenhagen, in 2013. Contura A/S had two marketed products at the time of its acquisition, Bulkamid® and Aquamid® . It also had a number of development programmes focused on additional uses of its hydrogel technology.
In prospect, the opportunities for new products include:
• approval of Bulkamid® in the United States (stress urinary incontinence)
• approval of Arthrosamid® in the EU (synovial implant for osteoarthritis)
• approval of Bulkamid® VUR in the EU and other territories (vesicoureteral reflux)
The Group has an established sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. It has offices in the UK, Denmark, Germany, France and Italy and employs some 45 staff Europe wide.
Contact Patrick Banks, CEO
1Phone number: +44 (0)20 7421 7400
Please visit our rebranded web page for further information:
www.contura.com
Juno Pharmaceuticals announced today that it has acquired Amneal Pharmaceuticals' injectables, ophthalmic, and oncology product portfolios in Australia.
“Juno is excited to add the Amneal Australia hospital injectable, ophthalmic, and oncology range to its growing portfolio. This Amneal portfolio complements many of Juno's existing assets nicely and Juno is particularly excited to be managing products such as Bicnu (carmustine),” said CEO and Managing Director of Juno Australia, Mark Crotty.
Juno is a rapidly-growing local Australian business that recorded its first full year of commercial sales in 2016. Juno’s business model is based on partnering across all stages of the commercial cycle and has a core focus on local Australian hospital customer needs. The acquisition of Amneal's portfolio is Juno Australia’s first since its formation in 2013 and when added to its existing product portfolio and strong pipeline, the acquisition is expected to position Juno as one of the largest generic injectable product hospital suppliers in the Australian market.
The acquisition takes effect from August 31st, 2017. Juno will work with Amneal to ensure a smooth transition of the business with suppliers and customers.
For all queries please contact:
Mark Crotty, +61 424 152 881
Contura A/S (“Contura”), a wholly owned subsidiary of Speciality European Pharma Limited (“SEP”), is pleased to announce that on 30 July 2017 it filed a Premarket Approval (“PMA”) application with the Federal Drug Administration (“FDA”) in the United States for the approval of Bulkamid® .
Bulkamid® is Contura’s proprietary medical device for the treatment of stress urinary incontinence (“SUI”). The product is currently marketed in more than 25 countries throughout the world. In 2014 the pivotal North American study for the product was published, reporting on the efficacy and safety of Bulkamid® for the treatment of female stress incontinence in a randomised, prospective, multicentre North American study. This North American study forms the basis of Contura’s PMA.
Commenting on the filing, Patrick Banks, Director of Contura, said:
“Since Contura’s acquisition by SEP in 2013 it has been the intention of the company to file a PMA in the United States. The completion of the pivotal North American study for the product provided the necessary data for the filing, but it was not until the completion of the management buyout of SEP in May 2016 that the company was provided with the necessary financial resources. We are excited by the opportunity this filing provides. The United States market is by far the largest market in the world for SUI products. With the current controversy surrounding the use of slings and meshes for SUI treatment, particularly in the United States, and the emerging data supporting Bulkamid’s more prominent use, we believe Bulkamid® is well positioned to be offered as the first line treatment of choice for SUI.”
About Bulkamid®
Bulkamid® is a homogenous hydrophilic hydrogel used in the treatment of female stress urinary incontinence. The product was granted CE approval in 2003 and is currently sold in more than 25 countries worldwide. Bulkamid® is delivered to the patient under endoscopic control using the Bulkamid® Urethral Bulking System.
About SEP
SEP is the parent company of a European group which specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily upon the fields of urology and urogynaecology. Its lead products are:
Bulkamid®
Aquamid®
Mitem®
Regurin® XL
Cystistat
SEP was founded in 2006 and built an experienced and accomplished management team. In 2013, SEP acquired Contura A/S, a Danish company based in Copenhagen. Contura A/S had two marketed products at the time of its acquisition by SEP, Bulkamid® and Aquamid® . It also had a number of development programmes focused upon additional uses of its hydrogel technology. In 2016, SEP was acquired by its management team in conjunction with new investors. SEP has established a sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. SEP has offices in the UK, Denmark, Germany, France and Italy.
Contact
Head Office:
Juno Pharmaceuticals Inc.
555 Richmond Street West, Suite 1004, Toronto,
Ontario M5V 3B1, Canada
+1 905 881 4410 Ext 203
Business Development:
Juno Pharmaceuticals Inc.
1st Floor, The Coach House, Cross Heyes,
Malmesbury SN16 9BE
+44 (0) 1666 848 450